JB Chemicals and Pharmaceuticals Ltd (JB Pharma) reported a strong financial performance for the third quarter of FY26, with consolidated revenue rising to INR 1,065 crore, an increase of around 11 percent compared to the same quarter last year.

The company’s operating performance improved during the quarter, with earnings before interest, tax, depreciation and amortisation (EBITDA) growing by about 13 percent year on year to INR 305 crore. This was supported by operating leverage, cost efficiencies and a favourable product mix. Net profit for Q3 FY26 stood at INR 198 crore, registering a 22 percent increase over the corresponding quarter of the previous fiscal year.

Growth was primarily driven by the domestic formulations business, which continued to see healthy traction across chronic therapy segments and key brands. The international formulations business also contributed to overall growth, while the contract development and manufacturing (CDMO) segment maintained steady progress.

JB Pharma reported an improvement in margins during the quarter, aided by stable raw material costs and disciplined pricing. The company stated that its strong balance sheet and robust cash flows position it well to sustain profitable growth in the coming quarters.